Oncotect, founded in Raleigh, is a biotech startup dedicated to pioneering early cancer screening for dogs. The company's core mission is to provide non-invasive, affordable, and accessible multi-cancer screening tests using dog urine. Their innovative approach leverages proprietary technology and C. elegans’ olfactory receptors to detect cancerous volatile metabolites. Oncotect aims to revolutionize veterinary oncology by offering a convenient and effective solution for early cancer detection.
Notable figures affiliated with Oncotect include leading veterinary oncologists and biotech investors who support the company's mission. The startup has achieved significant milestones, including the development of a patent-pending in-vitro test and widespread trust among veterinarians nationwide. Oncotect's impact is profound, offering pet owners peace of mind through early detection and contributing to the advancement of veterinary medicine.
